Taper group (n=116) | Usual care group (n=59) | Difference (95% CI) | Total (n=175) | |
---|---|---|---|---|
SvdH baseline* | 38.3 (49.3) | 42.1 (58.7) | −3.79 (−20.4 to 12.8) | 39.6 (52.5) |
SvdH 18 months* | 39.0 (49.6) | 42.2 (58.7) | −3.19 (−19.9 to 13.5) | 40.1 (52.7) |
Progression SvdH score* | 0.75 (1.5) | 0.15 (1.1) | 0.60 (0.16 to 1.0) | 0.55 (1.4) |
Progression erosion score* | 0.29 (0.8) | 0.12 (0.7) | 0.17 (−0.07 to 0.42) | 0.23 (0.8) |
Progression joint space narrowing* | 0.46 (1.2) | 0.03 (0.9) | 0.43 (0.07 to 0.78) | 0.32 (1.1) |
Progression >MCIC† | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Progression >SDC† | 5 (4) | 0 (0) | 5 (4) | 5 (3) |
Progression >0.5† | 37 (32) | 9 (15) | 28 (17) | 46 (26) |
*Mean with SD.
†Number (%) of patients.
MCIC, minimal clinical important change (8 units); Progression SvdH, Sharp-van der Heijde progression between baseline and 18 months; SDC, smallest detectable change (4.1 units); SvdH, Sharp-van der Heijde score.